Citadel Advisors LLC increased its position in Syneron Medical Ltd. (NASDAQ:ELOS) by 2.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,835 shares of the medical equipment provider’s stock after buying an additional 243 shares during the period. Citadel Advisors LLC’s holdings in Syneron Medical were worth $125,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. GSA Capital Partners LLP raised its position in Syneron Medical by 7.9% in the fourth quarter. GSA Capital Partners LLP now owns 22,552 shares of the medical equipment provider’s stock valued at $189,000 after buying an additional 1,654 shares in the last quarter. ClariVest Asset Management LLC acquired a new stake in shares of Syneron Medical during the first quarter worth $199,000. Campbell & CO Investment Adviser LLC raised its stake in shares of Syneron Medical by 28.6% in the first quarter. Campbell & CO Investment Adviser LLC now owns 22,781 shares of the medical equipment provider’s stock worth $240,000 after buying an additional 5,065 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Syneron Medical by 96.1% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 31,247 shares of the medical equipment provider’s stock worth $262,000 after buying an additional 15,312 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Syneron Medical during the fourth quarter worth approximately $409,000. 69.17% of the stock is owned by hedge funds and other institutional investors.

Shares of Syneron Medical Ltd. (ELOS) remained flat at $11.00 during midday trading on Thursday. 3,905 shares of the company were exchanged. Syneron Medical Ltd. has a 52-week low of $6.18 and a 52-week high of $11.43. The firm’s 50-day moving average is $10.90 and its 200 day moving average is $10.14.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/03/citadel-advisors-llc-has-125000-stake-in-syneron-medical-ltd-elos-updated-updated-updated.html.

ELOS has been the subject of a number of research reports. Maxim Group lowered Syneron Medical from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $12.00 to $11.00 in a research report on Friday, May 12th. BidaskClub lowered Syneron Medical from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.95.

About Syneron Medical

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.

Institutional Ownership by Quarter for Syneron Medical (NASDAQ:ELOS)

Receive News & Stock Ratings for Syneron Medical Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd. and related stocks with our FREE daily email newsletter.